NCT01509937View on ClinicalTrials.gov

Body Composition Monitor(BCM) Guided Fluid Management in Maintenance Hemodialysis (MHD) Patients

NACompletedINTERVENTIONAL
Enrollment

433

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
End Stage Renal Disease
Interventions
DEVICE

body bioimpedance spectroscopy device

Name of the device is BCM from Fresenius Medical Care D GmbH

DEVICE

Device

participants in control arm will not receive BCM measurement.

Trial Locations (1)

100034

Institute of Nephrology, Peking University First Hospital, Beijing

All Listed Sponsors
collaborator

Fresenius Medical Care (Shanghai) Co., Ltd

UNKNOWN

lead

Peking University First Hospital

OTHER

NCT01509937 - Body Composition Monitor(BCM) Guided Fluid Management in Maintenance Hemodialysis (MHD) Patients | Biotech Hunter | Biotech Hunter